AnaptysBio (NASDAQ:ANAB) Insider Paul Lizzul Sells 4,219 Shares

AnaptysBio, Inc. (NASDAQ:ANAB) insider Paul Lizzul sold 4,219 shares of the stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $43.26, for a total transaction of $182,513.94. Following the completion of the sale, the insider directly owned 33,303 shares of the company’s stock, valued at $1,440,687.78. This represents a 11.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

AnaptysBio Stock Performance

Shares of ANAB traded up $0.71 during mid-day trading on Tuesday, reaching $43.91. The stock had a trading volume of 466,030 shares, compared to its average volume of 381,205. The business has a fifty day moving average of $42.13 and a 200 day moving average of $31.12. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -15.57 and a beta of 0.32. AnaptysBio, Inc. has a 12 month low of $12.21 and a 12 month high of $52.47.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, beating the consensus estimate of ($1.06) by $1.58. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. The firm had revenue of $76.32 million for the quarter, compared to the consensus estimate of $15.83 million. On average, research analysts forecast that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio announced that its board has approved a share buyback plan on Friday, November 21st that allows the company to buyback $100.00 million in outstanding shares. This buyback authorization allows the biotechnology company to purchase up to 9.6% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ANAB. Truist Financial increased their target price on AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a research report on Monday, November 10th. Wedbush restated an “outperform” rating and issued a $50.00 price target on shares of AnaptysBio in a research note on Monday, November 24th. Barclays cut their price objective on shares of AnaptysBio from $70.00 to $55.00 and set an “overweight” rating for the company in a report on Wednesday, December 17th. Wall Street Zen raised shares of AnaptysBio from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 16th. Finally, Guggenheim reaffirmed a “buy” rating on shares of AnaptysBio in a research note on Thursday, December 18th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $55.40.

Institutional Trading of AnaptysBio

A number of large investors have recently added to or reduced their stakes in ANAB. Assenagon Asset Management S.A. boosted its position in shares of AnaptysBio by 4,852.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 839,934 shares of the biotechnology company’s stock valued at $25,719,000 after acquiring an additional 822,975 shares during the last quarter. Woodline Partners LP raised its stake in AnaptysBio by 63.1% during the first quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company’s stock valued at $14,705,000 after purchasing an additional 305,950 shares in the last quarter. 683 Capital Management LLC lifted its position in AnaptysBio by 155.6% during the second quarter. 683 Capital Management LLC now owns 500,000 shares of the biotechnology company’s stock valued at $11,100,000 after purchasing an additional 304,373 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its position in AnaptysBio by 2.7% during the third quarter. Jacobs Levy Equity Management Inc. now owns 378,452 shares of the biotechnology company’s stock valued at $11,588,000 after purchasing an additional 10,005 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its position in AnaptysBio by 145.6% in the third quarter. Arrowstreet Capital Limited Partnership now owns 370,458 shares of the biotechnology company’s stock worth $11,343,000 after acquiring an additional 219,648 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.